Chiara Cerrato
Overview
Explore the profile of Chiara Cerrato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carelli F, Cerrato C, Dong Y, Appert A, Dernburg A, Ahringer J
Sci Adv
. 2022 Dec;
8(50):eabo4082.
PMID: 36525485
The movement of selfish DNA elements can lead to widespread genomic alterations with potential to create novel functions. We show that transposon expansions in nematodes led to extensive rewiring of...
2.
Gal C, Carelli F, Appert A, Cerrato C, Huang N, Dong Y, et al.
Cell Rep
. 2021 Oct;
37(3):109835.
PMID: 34686342
The DREAM (dimerization partner [DP], retinoblastoma [Rb]-like, E2F, and MuvB) complex controls cellular quiescence by repressing cell-cycle and other genes, but its mechanism of action is unclear. Here, we demonstrate...
3.
Serizay J, Dong Y, Janes J, Chesney M, Cerrato C, Ahringer J
Genome Res
. 2020 Oct;
30(12):1752-1765.
PMID: 33093068
RNA profiling has provided increasingly detailed knowledge of gene expression patterns, yet the different regulatory architectures that drive them are not well understood. To address this, we profiled and compared...
4.
Beltran T, Barroso C, Birkle T, Stevens L, Schwartz H, Sternberg P, et al.
Dev Cell
. 2019 Feb;
48(6):793-810.e6.
PMID: 30713076
Piwi-interacting RNAs (piRNAs) are important for genome regulation across metazoans, but their biogenesis evolves rapidly. In Caenorhabditis elegans, piRNA loci are clustered within two 3-Mb regions on chromosome IV. Each...
5.
Bonello F, DAgostino M, Moscvin M, Cerrato C, Boccadoro M, Gay F
Expert Opin Biol Ther
. 2018 Nov;
18(12):1209-1221.
PMID: 30394809
Introduction: Multiple myeloma (MM) is a currently incurable hematologic tumor with heterogeneous clinical behavior and prognosis. During the last years, survival improved due to a better understanding of MM biology...
6.
Janes J, Dong Y, Schoof M, Serizay J, Appert A, Cerrato C, et al.
Elife
. 2018 Oct;
7.
PMID: 30362940
An essential step for understanding the transcriptional circuits that control development and physiology is the global identification and characterization of regulatory elements. Here, we present the first map of regulatory...
7.
Mina R, Petrucci M, Corradini P, Spada S, Patriarca F, Cerrato C, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Jun;
18(8):533-540.
PMID: 29910180
Background: High-dose therapy with autologous stem cell transplantation (HDT-ASCT) and maintenance treatment with novel agents are the best options for patients with newly diagnosed multiple myeloma, increasing the rate of...
8.
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, et al.
J Cancer Res Clin Oncol
. 2018 Apr;
144(7):1357-1366.
PMID: 29675792
Purpose: Maintenance demonstrated to improve survival in newly diagnosed multiple myeloma (NDMM) patients and the achievement of complete response (CR) is a strong predictor of survival. Nevertheless, the role of...
9.
Mina R, DAgostino M, Cerrato C, Gay F, Palumbo A
Leuk Lymphoma
. 2016 Nov;
58(7):1538-1547.
PMID: 27819179
Plasma cell leukemia (PCL) is a rare, but very aggressive, plasma cell dyscrasia, representing a distinct clinicopathological entity as compared to multiple myeloma (MM), with peculiar biological and clinical features....
10.
Mina R, Cerrato C, Bernardini A, Aghemo E, Palumbo A
Expert Opin Pharmacother
. 2015 Dec;
17(2):181-92.
PMID: 26684262
Introduction: Novel agents and the availability of autologous stem-cell transplantation have revolutionized the treatment of patients with multiple myeloma. First-generation novel agents namely thalidomide, lenalidomide, and bortezomib have significantly improved...